Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
Top Cited Papers
Open Access
- 19 August 2009
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (7) , 750-757
- https://doi.org/10.1001/jama.2009.1201
Abstract
On June 8, 2006, the Food and Drug Administration (FDA) licensed the quadrivalent human papillomavirus recombinant vaccine (qHPV) (Gardasil; Merck & Co, Inc, Whitehouse Station, New Jersey) for females aged 9 to 26 years to prevent infection with genital human papillomavirus (HPV) types 6, 11, 16, and 18.1 Later that month, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of females aged 11 to 12 years with 3 doses of qHPV and catch-up vaccination for females aged 13 to 26 years. Doses are administered intramuscularly on a schedule of 0, 2, and 6 months.2 The viruses HPV-16 and HPV-18 can cause cervical cancer, other anogenital cancers, and precancerous or dysplastic lesions and are responsible for about 70% of cervical cancers worldwide.3 The viruses HPV-6 and HPV-11 are the most common causes of genital warts.Keywords
This publication has 15 references indexed in Scilit:
- Novel Statistical Tools for Monitoring the Safety of Marketed DrugsClinical Pharmacology & Therapeutics, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007
- Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR. Recommendations and Reports, 2007
- Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult WomenPediatrics, 2006
- Understanding vaccine safety information from the Vaccine Adverse Event Reporting SystemThe Pediatric Infectious Disease Journal, 2004
- Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of CausalityJNCI Monographs, 2003
- Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA??s Spontaneous Reports DatabaseDrug Safety, 2002
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001
- The vaccine adverse event reporting system (VAERS)Vaccine, 1994
- Guillain-Barré syndrome: Its epidemiology and associations with influenza vaccinationAnnals of Neurology, 1981